Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis

Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia

“…Our survey demonstrated that 5-ASA/SASP was preferred by almost all the physicians as the first-line therapy for induction and maintenance in mild-moderate UC patients, which accords with the solid evidences reported before [ 14 - 16 ]. In this group of patients, 5-ASA/SASP will remain the mainstay of therapy due to its efficacy and tolerance [ 11 ].…”

Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia

“…Our survey demonstrated that 5-ASA/SASP was preferred by almost all the physicians as the first-line therapy for induction and maintenance in mild-moderate UC patients, which accords with the solid evidences reported before [ 14 - 16 ]. In this group of patients, 5-ASA/SASP will remain the mainstay of therapy due to its efficacy and tolerance [ 11 ].…”

Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study

“…The magnitude of the effect, estimated by the number of patients in clinical remission at week 8, was similar to other studies of oral mesalamine dose escalations [30][31][32]. Our findings are further supported by the reductions in endoscopic activity and quality of life indices.…”

The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis

“…This 15.2% difference is very similar to the magnitude of difference reported in other trials of mesalamine for the treatment of patients with mildly to moderately active UC. 4 Thus, although the 9.4% difference observed in the ITT analysis was lower than might be expected, in the population deemed eligible by the central reader, the magnitude of the treatment effect was in line with previous studies. Furthermore, although statistical significance was already evident in the ITT analyses for the majority of the secondary efficacy outcomes, the magnitude of the treatment effect observed was consistently greater in the analyses performed on the population of patients deemed eligible by the central reader.…”

Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia

“…Our survey demonstrated that 5-ASA/SASP was preferred by almost all the physicians as the first-line therapy for induction and maintenance in mild-moderate UC patients, which accords with the solid evidences reported before [ 14 - 16 ]. In this group of patients, 5-ASA/SASP will remain the mainstay of therapy due to its efficacy and tolerance [ 11 ].…”

Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study

“…The magnitude of the effect, estimated by the number of patients in clinical remission at week 8, was similar to other studies of oral mesalamine dose escalations [30][31][32]. Our findings are further supported by the reductions in endoscopic activity and quality of life indices.…”

The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis

“…This 15.2% difference is very similar to the magnitude of difference reported in other trials of mesalamine for the treatment of patients with mildly to moderately active UC. 4 Thus, although the 9.4% difference observed in the ITT analysis was lower than might be expected, in the population deemed eligible by the central reader, the magnitude of the treatment effect was in line with previous studies. Furthermore, although statistical significance was already evident in the ITT analyses for the majority of the secondary efficacy outcomes, the magnitude of the treatment effect observed was consistently greater in the analyses performed on the population of patients deemed eligible by the central reader.…”

Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia

“…Our survey demonstrated that 5-ASA/SASP was preferred by almost all the physicians as the first-line therapy for induction and maintenance in mild-moderate UC patients, which accords with the solid evidences reported before [ 14 - 16 ]. In this group of patients, 5-ASA/SASP will remain the mainstay of therapy due to its efficacy and tolerance [ 11 ].…”

Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study

“…The magnitude of the effect, estimated by the number of patients in clinical remission at week 8, was similar to other studies of oral mesalamine dose escalations [30][31][32]. Our findings are further supported by the reductions in endoscopic activity and quality of life indices.…”

The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis

“…This 15.2% difference is very similar to the magnitude of difference reported in other trials of mesalamine for the treatment of patients with mildly to moderately active UC. 4 Thus, although the 9.4% difference observed in the ITT analysis was lower than might be expected, in the population deemed eligible by the central reader, the magnitude of the treatment effect was in line with previous studies. Furthermore, although statistical significance was already evident in the ITT analyses for the majority of the secondary efficacy outcomes, the magnitude of the treatment effect observed was consistently greater in the analyses performed on the population of patients deemed eligible by the central reader.…”